在巨细胞动脉炎患者的CD8+ T细胞中增加了干扰素I型活性的证据
Marieke van Nieuwland1,2, Idil Esen2, Rosanne D Reitsema2,3
1Department of Rheumatology and Clinical Immunology, Hospital Group Twente (Ziekenhuisgroep Twente), Almelo, Netherlands.
Frontiers in immunology
|July 3, 2023
概括
干扰素I型 (IFN-I) 活性在巨细胞动脉炎 (GCA) 患者的CD8+T细胞中升高. 这表明IFN-I在GCA病变发生过程中发挥作用,并可能提供新的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 血管生物学 血管生物学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 巨细胞动脉炎 (GCA) 是一种大血管血管炎,对其病变的理解有限.
- 干扰素I型 (IFN-I) 与自身免疫性疾病有关,但其在GCA中的作用尚未确立.
- IFN-I信号涉及JAK-STAT通路,影响基因表达.
研究的目的:
- 为了研究IFN-I活性在GCA患者的CD8+T细胞中的作用.
- 探索潜在的IFN-I相关生物标志物和GCA的治疗策略.
主要方法:
- 分析了IFN-α刺激的CD8+ T细胞中的光-STAT (pSTAT) 1,3和5表达,这些细胞来自GCA患者,健康对照组和感染对照组,使用光流和光细胞条形编码.
- 在动脉活检 (TAB) 和来自GCA患者和对照者的大动脉组织中通过免疫组织化学评估IFN-I诱导的抗菌病毒蛋白A (MxA) 表达.
主要成果:
- 从GCA患者的IFN-α刺激的CD8+T细胞中观察到增加的pSTAT1表达.
- 与对照组相比,MxA在GCA患者的TAB和大动脉组织中明显更为普遍.
- 在受影响的组织中,MxA表达部分与CD8+ T细胞同局部化.
结论:
- 结果表明,GCA患者的CD8+T细胞内IFN-I活性增加,无论是系统性还是局部性.
- 这些发现支持进一步研究IFN-I驱动的生物标志物和GCA的新疗法.
相关概念视频
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
175
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175


